Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.

@article{Lim2006RandomizedDS,
  title={Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.},
  author={Seng Gee Lim and Zahary Krastev and Tay Meng Ng and Grigor Mechkov and Iskren Andreev Kotzev and Sing Mei Chan and Elsa Mondou and Andrea Snow and Jeff Sorbel and Franck Rousseau},
  journal={Antimicrobial agents and chemotherapy},
  year={2006},
  volume={50 5},
  pages={
          1642-8
        }
}
Emtricitabine (FTC) is approved for the treatment of human immunodeficiency virus. FTC and clevudine (CLV) have activity against hepatitis B virus (HBV). This report summarizes the results of a double-blind, multicenter study of patients with chronic hepatitis B who had completed a phase 3 study of FTC and were randomized 1:1 to 200 mg FTC once daily (QD) plus 10 mg CLV QD or 200 mg FTC QD plus placebo for 24 weeks with 24 weeks of follow-up. One hundred sixty-three patients were treated (82… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 23 CITATIONS

Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.

  • Liver international : official journal of the International Association for the Study of the Liver
  • 2012
VIEW 2 EXCERPTS
CITES BACKGROUND

Management of chronic hepatitis B.

  • European journal of gastroenterology & hepatology
  • 2011